$CTMX
CytomX Therapeutics Inc

2021 Q1 Form 10-Q Financial Statement

#000156459021024969 Filed on May 06, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $15.97M $49.59M
YoY Change -67.8% 68.2%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.230M $9.570M
YoY Change -3.55% -1.03%
% of Gross Profit
Research & Development $22.37M $42.81M
YoY Change -47.74% 17.69%
% of Gross Profit
Depreciation & Amortization $600.0K $600.0K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $31.60M $52.39M
YoY Change -39.68% 44.01%
Operating Profit -$15.63M
YoY Change
Interest Expense $70.00K $1.080M
YoY Change -93.52% -56.8%
% of Operating Profit
Other Income/Expense, Net $5.000K $10.00K
YoY Change -50.0% -116.39%
Pretax Income -$15.55M -$1.710M
YoY Change 809.36% -87.9%
Income Tax $0.00 -$13.91M
% Of Pretax Income
Net Earnings -$15.55M $12.21M
YoY Change -227.44% -186.41%
Net Earnings / Revenue -97.39% 24.61%
Basic Earnings Per Share
Diluted Earnings Per Share -$255.0K $267.1K
COMMON SHARES
Basic Shares Outstanding 60.97M 45.72M
Diluted Shares Outstanding 60.97M 47.04M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $393.8M $247.9M
YoY Change 58.85% -37.49%
Cash & Equivalents $329.7M $143.3M
Short-Term Investments $64.10M $104.6M
Other Short-Term Assets $5.500M $9.100M
YoY Change -39.56% 8.33%
Inventory
Prepaid Expenses
Receivables $800.0K $130.0M
Other Receivables $0.00 $13.10M
Total Short-Term Assets $400.0M $400.1M
YoY Change -0.02% -1.23%
LONG-TERM ASSETS
Property, Plant & Equipment $28.90M $32.10M
YoY Change -9.97% -7.76%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.200M $1.379M
YoY Change 132.05% -40.04%
Total Long-Term Assets $34.20M $36.56M
YoY Change -6.46% -7.2%
TOTAL ASSETS
Total Short-Term Assets $400.0M $400.1M
Total Long-Term Assets $34.20M $36.56M
Total Assets $434.2M $436.7M
YoY Change -0.56% -1.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.600M $3.782M
YoY Change -31.25% -60.19%
Accrued Expenses $18.83M $28.35M
YoY Change -33.58% 25.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $98.00M $106.0M
YoY Change -7.55% 10.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $190.1M $260.9M
YoY Change -27.14% 15.6%
Total Long-Term Liabilities $190.1M $260.9M
YoY Change -27.14% 15.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $98.00M $106.0M
Total Long-Term Liabilities $190.1M $260.9M
Total Liabilities $288.1M $366.9M
YoY Change -21.47% 13.98%
SHAREHOLDERS EQUITY
Retained Earnings -$465.7M
YoY Change
Common Stock $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $146.0M $69.77M
YoY Change
Total Liabilities & Shareholders Equity $434.2M $436.7M
YoY Change -0.58% -1.75%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$15.55M $12.21M
YoY Change -227.44% -186.41%
Depreciation, Depletion And Amortization $600.0K $600.0K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$29.94M -$49.74M
YoY Change -39.8% 27.44%
INVESTING ACTIVITIES
Capital Expenditures $982.0K $1.049M
YoY Change -6.39% -42.83%
Acquisitions
YoY Change
Other Investing Activities $60.00M $3.500M
YoY Change 1614.29% -120.83%
Cash From Investing Activities $59.01M $2.441M
YoY Change 2317.53% -113.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $107.7M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 108.7M 2.157M
YoY Change 4941.03% 363.87%
NET CHANGE
Cash From Operating Activities -29.94M -49.74M
Cash From Investing Activities 59.01M 2.441M
Cash From Financing Activities 108.7M 2.157M
Net Change In Cash 137.8M -45.14M
YoY Change -405.29% -21.04%
FREE CASH FLOW
Cash From Operating Activities -$29.94M -$49.74M
Capital Expenditures $982.0K $1.049M
Free Cash Flow -$30.92M -$50.79M
YoY Change -39.11% 24.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 ctmx Net Operating Loss Carryback Period
NetOperatingLossCarrybackPeriod
P5Y
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y9M
CY2020Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y6M
CY2021Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Liabilities
Liabilities
288136000
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65002897
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65002897
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
611733000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-43000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-465669000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
146022000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
434158000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15971000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-42000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1640000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
74000
CY2021Q1 ctmx Increase Decrease In Accrued And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedAndOtherLiabilitiesNoncurrent
-5096000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9227000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-13911000
CY2021Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.26
CY2020Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.27
CY2021Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.26
CY2020Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.26
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60968111
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45723955
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60968111
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47044774
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
4000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
279000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15550000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
12484000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
49803000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
107712000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1023000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3034000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-15554000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
146022000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
51113000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-15554000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
12205000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
36000
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
36000
CY2021Q1 ctmx Depreciation And Amortization Excluding Amortization Of Intangible Assets
DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
638000
CY2020Q1 ctmx Depreciation And Amortization Excluding Amortization Of Intangible Assets
DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
601000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-141000
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
127000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3034000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4013000
CY2021Q1 ctmx Noncash Lease Expense
NoncashLeaseExpense
-759000
CY2020Q1 ctmx Noncash Lease Expense
NoncashLeaseExpense
-700000
CY2020Q1 ctmx Increase Decrease In Accrued And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedAndOtherLiabilitiesNoncurrent
-3315000
CY2021Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
59994000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
59012000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
107712000
CY2021Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Description of the Business</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CytomX Therapeutics, Inc. (the “Company”) is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. The Company aims to build a commercial-stage enterprise to maximize its impact on the treatment of cancer. The Company is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its Probody® therapeutic technology platform that could meaningfully improve outcomes for cancer patients. Its proprietary and unique Probody technology platform is designed to enable “conditional activation” of antibody-based drugs within the tumor while minimizing drug activity in healthy tissues and in circulation. The Company is located in South San Francisco, California and was incorporated in the state of Delaware in September 2010.</p>
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p>
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
329666000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
191859000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
143286000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2020Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
330583000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
192776000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
144203000
CY2020Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.27
CY2021Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.26
CY2020Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.26
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
256298000
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
0
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-15554000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
12205000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60968111
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45723955
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60968111
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45723955
CY2020Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1320819
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60968111
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47044774
CY2021Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.26
CY2021Q1 ctmx Cash Cash Equivalents And Short Term Investments Amortized Cost Basis
CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis
346238000
CY2021Q1 ctmx Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax
10000
CY2021Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
346248000
CY2020Q4 ctmx Cash Cash Equivalents And Short Term Investments Amortized Cost Basis
CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis
256292000
CY2020Q4 ctmx Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2021Q1 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
8486000
CY2020Q4 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
10092000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5043000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8362000
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1189000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
815000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3297000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3195000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
816000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
595000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18831000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23059000
CY2021Q1 us-gaap Revenues
Revenues
15971000
CY2020Q1 us-gaap Revenues
Revenues
49593000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5341720
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
261130000
CY2021Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
15215000
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
245916000
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
245900000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10929530
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.77
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2792347
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.87
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
322507
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.17
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1535118
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.15
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11864252
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.25
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.11
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3034000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4013000
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
1300000
CY2020Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
1300000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1273000
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1239000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21736000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22495000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3297000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3195000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20807000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21675000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
24870000
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0825
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0825
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3856000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5273000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5420000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5572000
CY2021Q1 ctmx Lessee Operating Lease Liability Payments Due Year Four And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter
10116000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
30237000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6133000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
24104000
CY2020Q1 ctmx Percentage Of Taxable Income From Net Operating Losses For Suspension Of Annual Deduction Limitation
PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation
0.80

Files In Submission

Name View Source Status
0001564590-21-024969-index-headers.html Edgar Link pending
0001564590-21-024969-index.html Edgar Link pending
0001564590-21-024969.txt Edgar Link pending
0001564590-21-024969-xbrl.zip Edgar Link pending
ctmx-10q_20210331.htm Edgar Link pending
ctmx-10q_20210331_htm.xml Edgar Link completed
ctmx-20210331.xsd Edgar Link pending
ctmx-20210331_cal.xml Edgar Link unprocessable
ctmx-20210331_def.xml Edgar Link unprocessable
ctmx-20210331_lab.xml Edgar Link unprocessable
ctmx-20210331_pre.xml Edgar Link unprocessable
ctmx-ex102_137.htm Edgar Link pending
ctmx-ex103_136.htm Edgar Link pending
ctmx-ex311_10.htm Edgar Link pending
ctmx-ex312_9.htm Edgar Link pending
ctmx-ex321_7.htm Edgar Link pending
ctmx-ex322_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
guca3cel2yty000001.jpg Edgar Link pending
guca3cel2yty000002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending